Thompson Reuters Business Models Event
Managing the Trademark Asset Lifecycle

Tweets

July 29

If Celgene is successful with this, then the BIO and PhRMA case for an IPR carve-out is surely destroyed. https://t.co/BRmUShU4L4

July 29

This will be interesting ... https://t.co/BRmUShU4L4

July 29

Interesting that the Bessen & Meurer $29bn claim dropped. But even this RPX amount largely made up of royalties. https://t.co/asQPp14HaT

Blog

28 Jul 2015
New court filings throw light on ZTE’s “PR battle” with Vringo

The multi-year, worldwide and ongoing litigation battle between ZTE and non-practising entity (NPE) Vringo took an interesting twist last week when a series of internal ZTE documents were filed with a New York court. The documents, which largely consist of communications between ZTE staff, detail how the Chinese telecom company has set out to wage a “PR battle” against Vringo as...

28 Jul 2015
Chinese VC firm to target European high tech companies with new $5 billion takeover fund

Chinese investment firm GSR Capital yesterday announced the launch of a $5 billion M&A fund, which it said would be used for large-scale buyouts of western technology companies in sectors including life sciences, wireless communications and clean energy. Chairman Sonny Wu told Bloomberg that the firm will mainly target European businesses, in what could be another sign that the...

27 Jul 2015
Pharma and biotech companies can't justify IPR opt outs, but you can see why they are asking for them

The pharmaceutical and biotechnology industries seem to be stepping up their attempts to secure a carve-out for biopharmaceutical patents from the IPR process. Last week, Jim Greenwood, the president and CEO of BIO and John Castellani, the president and CEO of PhRMA, put together an opinion piece for The Hill in which they claimed that: “Predatory hedge funds are short-selling the...

Explore the current issue

Quality patents becomes the new mantra in China

After several years of intensive growth in patent filings and grants, the Chinese government and businesses in the country are turning their attention to improving the strategic value of intellectual property. A group of industry insiders discuss the issues this raises

The world's leading patent practitioners

IAM Patent 1000

The definitive guide to leading patent lawyers, attorneys and firms in over 40 jurisdictions, with a special section on expert witnesses in the United States.

Visit site

The world's leading IP strategists

IAM Strategy 300

A directory of individuals identified following a detailed research process as global leaders in providing IP value creation expertise to rights owners.

Visit site
Market intelligence

Market intelligence

Annual IAM supplements and management reports that take an in-depth look at specific areas of IP value creation concern and opportunity.

Visit site
IPBC

IPBC

Unique in the global IP marketplace, IPBC events bring together corporate leaders, aggregators, investors and other intermediaries to discuss key issues, network and do deals.

Visit site
IP Hall of Fame

IP Hall of Fame

A project designed to recognise the outstanding contributions that individual men and women have made towards the creation of today’s global IP system.

Visit site
Upcoming event

Upcoming event

IPBC Asia, November 8-10 2015 – Tokyo, Japan This is the only event in the region that focuses on how IP owners can strategically use intellectual property to secure greater operational flexibility, drive revenues, enhance bottom-line returns, increase shareholder value and provide leverage in the financial markets.

View all events
Subscribe

Subscribe

IAM is a unique publication which focuses on the many ways in which intellectual property and intangible assets can be used to create corporate value.

Subscribe now
International reports

International reports

Weekly updates from IAM’s team of international correspondents looking at recent developments in IP law and practice, business and finance.

Visit site